REFRACTORY LANGERHANS CELL HISTIOCYTOSIS
Clinical trials for REFRACTORY LANGERHANS CELL HISTIOCYTOSIS explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY LANGERHANS CELL HISTIOCYTOSIS trials appear
Sign up with your email to follow new studies for REFRACTORY LANGERHANS CELL HISTIOCYTOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare, recurrent blood cell disorder
Disease control Recruiting nowThis study is testing an oral medication called tovorafenib (DAY101) in children and young adults with Langerhans cell histiocytosis (LCH) that has come back or hasn't responded to previous treatments. LCH is a rare disorder where too many immune cells build up and can damage bon…
Matched conditions: REFRACTORY LANGERHANS CELL HISTIOCYTOSIS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New pill aims to turn immune system against tough blood cancers
Disease control Recruiting nowThis early-stage study is testing a new oral medication called Q702 for patients with advanced blood cancers and rare immune cell disorders that have not responded to standard treatments. The main goals are to find the safest dose and see what side effects occur. Researchers hope…
Matched conditions: REFRACTORY LANGERHANS CELL HISTIOCYTOSIS
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC